Levine Leichtman Capital Partners Sells Therapeutic Research Center
Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company Therapeutic Research Center (“TRC” or the “Company”) to Colibri Group, a portfolio company of Gridiron Capital.
- Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company Therapeutic Research Center (“TRC” or the “Company”) to Colibri Group, a portfolio company of Gridiron Capital.
- TRC is a leading provider of independent, evidence-based continuing education and training for healthcare professionals and institutions with a particular content focus on drug therapy recommendations and medication management.
- Over one million healthcare professionals and approaching four thousand hospitals rely on TRC’s advisory and education services to access concise, unbiased and timely information.
- TRC was an investment of Levine Leichtman Capital Partners V, L.P.
Morgan Stanley & Co. LLC served as the lead financial advisor to TRC, with support from William Blair & Company, LLC and Deloitte Corporate Finance LLC, and Kirkland & Ellis LLP served as legal counsel in connection with the sale.